Psych CASC / OSCE · Psychopharmacology — SNRIs and NRIs
Starting venlafaxine after SSRI — dual action, BP and discontinuation (CASC)
CASC-style communication station: explain SNRI rationale after SSRI, honest dual-action dose language, BP monitoring, sexual side-effects, discontinuation vs addiction framing, safety-netting and follow-up.
On this page & tools
Target exams
Station instructions (candidate)
You have 7 minutes. Speak with the patient (and partner if engaged). Explain why a change from escitalopram is reasonable, what an SNRI is in plain language without overselling “always stronger dual action,” propose a venlafaxine XR start and review plan including blood pressure checks, address “addiction/withdrawal” fears accurately, mention sexual side-effects, and safety-net for early worsening mood or rare dangerous combinations. Do not guarantee remission. Do not dismiss online fears — reframe with evidence.[1][2][4][7]
Marking domains
Empathy and agenda setting; accurate plain-language mechanism (serotonin and, at higher doses, noradrenaline systems); STAR*D-style equipoise that venlafaxine is one good switch option not the only magic drug; dose and titration clarity; BP monitoring; discontinuation vs addiction distinction; sexual side-effect honesty; crisis and early-review plan; partner involvement; no MAOI improvisation.[1][3][4][5][8]
Model communication map
- Open: thank them; summarise incomplete response on an adequate escitalopram trial; check what “dual” and “withdrawal” mean to her.[7]
- Why change: many people need a second step; large sequential-care evidence supports switching after SSRI non-remission to options including venlafaxine XR, with similar average outcomes to other switches — we individualise.[1]
- What SNRI means: medicines that act on serotonin and noradrenaline pathways; with venlafaxine the noradrenaline part is more at higher doses — so we start carefully and only increase if needed, rather than promising instant dual power on day one.[2]
- Plan example: cross-taper off escitalopram while starting venlafaxine XR 75 mg (or 37.5 mg first if she is activation-sensitive), review in 1–2 weeks, consider increase toward 150–225 mg only if tolerated and still symptomatic; BP check each step.[3][7]
- “Heart damage” talk: can raise blood pressure in some people, more as dose rises — that is why we measure BP, not because everyone gets heart attacks; report severe headache, chest pain or very high home readings.[3]
- “Addiction” talk: stopping suddenly can cause short-lived discontinuation symptoms (dizziness, electric-shock feelings, flu-like) because the medicine leaves the system quickly — that is not the same as opioid addiction; we will taper when stopping.[4]
- Sexual function: many antidepressants can affect sex drive, arousal or orgasm — we will ask at reviews and can adjust plan rather than suffer in silence.[5]
- Safety: more contact early if mood worsens, agitation or suicidal thoughts; list all other medicines/supplements (avoid MAOI combinations and random online stacks).[8][7]
- Close: written plan, questions, crisis contacts; optional psychology alongside medicine.[6][7]
Common fails
- Promising venlafaxine is always stronger than every SSRI for every person.[6]
- Ignoring BP or sexual side-effects.[3][5]
- Calling discontinuation “proof of addiction.”[4]
- Starting 225–375 mg on day one without titration talk.[2]
- Dismissing the partner or online fears without accurate reframing.
References
- [1]Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression N Engl J Med, 2006.PMID 16554525
- [2]Blier P, Saint-André E, Hébert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers Int J Neuropsychopharmacol, 2007.PMID 16690005
- [3]Thase ME Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients J Clin Psychiatry, 1998.PMID 9818630
- [4]Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research J Clin Psychiatry, 2006.PMID 16683860
- [5]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
- [6]Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 2018.PMID 29477251
- [7]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
- [8]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664